Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose

European Journal of Clinical Investigation

Volumn 26, Issue 8, 1996, Pages 668-675

  Von Ahsen, N ^a   Helmhold, M ^a   Eisenhauer, T ^a,b   Armstrong, V W ^a   Oellerich, M ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Gemeinschaftsklinikum Mittelrhein   (Germany)

Author keywords

Apolipoprotein(a); Corticosteroid; Cyclosporin; Immunosuppression; Lipoprotein(a); Phenotype; Renal transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GLUCOCORTICOID; LIPOPROTEIN A; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL;

EID: 0029769263     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.1996.tb02151.x     Document Type: Article

References (34)

1. Raine AEG, MacMahon SH, Selwood NH, Wing AJ, Brunner FP. Mortality from myocardial infarction in patients on renal replacement therapy in the UK (abstract). Nephrol Dial Transplant 1991;6:902
2. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991;31(Suppl): S29-34.
3. Armstrong VW, Cremer P, Eberle E et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986;62:249-57.
4. Seed M, Hoppichler F, Reaveley D et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990;322:1494-9.
5. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987;33:721.
6. Parsy D, Dracon M, Cachera C et al. Lipoprotein abnormalities in chronic haemodialysis patients. Nephrol Dial Transplant 1988;3:51-6.
7. Haffner SM, Gruber KK, Aldrete G, Jr., Morales PA, Stern MP, Tuttle KR. Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol 1992;3:1156-62.
8. Kandoussi A, Cachera C, Pagniez D, Dracon M, Fruchart JC, Tacquet A. Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD. Kidney Int 1992;42:424-5.
9. Auguet T, Senti M, Rubies-Prat J et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 1993;8:1099-103.
10. Hirata K, Kikuchi S, Saku K et al. Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with without diabetes mellitus. Kidney Int 1993;44:1062-70.
11. Fiorini F, Masturzo P, Mij M, Bertolini S. Lipoprotein(a) levels in hemodialysis patients: Relation to glucose intolerance and hemodialysis duration. Nephron 1995;70:500-1.
12. Kronenberg F, Konig P, Neyer U et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995;6:110-20.
13. Takegoshi T, Kitoh C, Yamazaki Y. A study of clinical significance of Lp[a] lipoprotein in patients with chronic renal failure treated by hemodialysis. Nippon Jinzo Gakkai Shi 1990;32:667-71.
14. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. Aust NZ J Med 1992;22:243-48.
15. Buggy D, Breathnach A, Keogh B, Cooke T, Feely J. Lipoprotein(a) and treatment of chronic renal disease. J Intern Med 1993;234:453-5.
16. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. High serum lipoprotein(a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol 1992;38:271-6.
17. Murphy BG, McNamee P, Duly E, Henry W, Archbold P, Trinick T. Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis. Atherosclerosis 1992;93:53-7.
18. Thillet J, Faucher C, Issad B, Allouache M, Chapman J, Jacobs C. Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993;22:226-32.
19. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Lipoprotein(a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993;8:609-13.
20. Murphy BG, McNamee PT. Apolipoprotein(a) concentration decreases following renal transplantation. Nephrol Dial Transplant 1992;7:174-5.
21. Black IW, Wilcken DE. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem 1992;38:353-7.
22. Kronenberg F, Konig P, Lhotta K et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 1994;14:1399-404.
23. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet 1993;341:268-70.
24. Azrolan N, Brown CD, Thomas L et al. Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients. Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients. Arterioscler Thromb 1994;14:1393-8.
25. Hilbrands LB, Demacker PN, Hoitsma AJ. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993;341:765-6.
26. Helmhold M, Bigge J, Muche R et al. Contribution of the apo[a] phenotype to plasma Lp[a] concentrations shows considerable ethnic variation. J Lipid Res 1991;32:1919-28.
27. Aoki K, Kawai S. Glucocorticoid therapy decreases serum lipoprotein (a) concentration in rheumatic diseases. Intern Med 1993;32:382-6.
28. Dieplinger H, Lackner C, Kronenberg F et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993;91:397-401.
29. Schumacher M, Kessler A, Bahlmann G, Wood WG. Acute changes in concentrations of apolipoproteins A-I, B, C-II and lipoprotein(a) in serum covering the period from directly before to 48 h after chronic haemodialysis. Eur J Clin Chem Clin Biochem 1994;32:123-5.
30. Oida K, Takai H, Maeda H et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 1992;38:2244-8.
31. Berg AL, Nilsson-Ehle P. Direct effects of corticotropin on plasma lipoprotein metabolism in man-studies in vivo and in vitro. Metabolism 1994;43:90-97.
32. Henkin Y, Como JA, Oberman A. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 1992;267:961-8.
33. Bittar AE, Ratcliffe PJ, Richardson AJ et al. The prevalence of hyperlipidemia in renal transplant recipients. Associations with immunosuppressive and antihypertensive therapy. Transplantation 1990;50:987-92.
34. Brown JH, Anwar N, Short CD et al. Serum lipoprotein(a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant 1993;8:863-7.